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Abstract
AbstractVernal keratoconjunctivitis (VKC) is an allergic, bilateral, recurrent inflammatory disorder 
of the conjunctiva and the cornea that has a seasonal incidence. It affects young males more than 
females in age bracket of 3 to 16.  In the majority of cases, symptoms resolve at puberty, but some 
may run into adulthood. Diagnosis is based typically on clinical signs and symptoms. The cause 
of the disease is not clearly known, but it is often associated with atopic diseases such as asthma or 
eczema and is probably due to a longstanding allergic reaction.  
The disease consists clinically of the palpebral, limbal and mixed types. Its management has been a 
great challenge to eye care providers because of its recurrent nature, the large number of individuals 
who are affected, wrong diagnoses, and lack of judicious drug administration. The disease has the 
potential of producing serious vision-threatening complications if not adequately managed. This 
case report also reviews the diagnosis and management options for patients with mixed VKC and 
demonstrates the importance of the clinician’s role in taking a careful case history and in modifying 
treatment when necessary throughout care.
Keywords:  Shield ulcer, giant papillae, superficial keratopathy, supratarsal injection, 
local concoction.
Résumé
La kératoconjonctivite vernale (KCV) est une inflammation allergique, bilatérale et récurrente de 
la conjonctive et de la cornée dont l’incidence est saisonnière. Elle sévit plus chez les hommes que 
chez les femmes dans la tranche d’âge trois à seize ans chez les jeunes. Dans la majorité des cas, 
les symptômes disparaissent à la puberté, mais dans certains cas, ils peuvent persister jusqu’à l’âge 
adulte. Le diagnostic repose normalement sur les signes et symptômes cliniques. La cause de cette 
affection n’est pas clairement établie, mais elle se trouve souvent liée à des affections atopiques comme 
l’asthme ou l’eczéma et est probablement imputable à une réaction allergique de vieille date. Elle est 
cliniquement des types palpébral, limbique et mixte. Sa prise en charge a présenté tout un défi pour 
les soignants oculovisuels à cause de son caractère récurrent, du grand nombre de sujets touchés, des 
erreurs de diagnostic et de l’absence de posologie judicieuse. L’affection risque d’engendrer de graves 
complications qui viendront menacer la vue si la maladie n’est pas convenablement prise en charge. 
Dans cette étude de cas, nous passerons aussi en revue les options de diagnostic et de gestion dans 
le cas des patients atteints d’une KCV du type mixte et nous démontrerons l’importance du rôle du 
clinicien qui doit relever soigneusement les antécédents et modifier le traitement si nécessaire tout au 
long des soins.
Mots clés :  Ulcère de la cornée, papilles géantes, kératite superficielle, injection supratarsienne, 
préparation locale.
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Introduction 
Allergic conjunctivitis is the inflammation of the conjunctiva 
due to allergens. The inflammation caused by the allergens may 
be seasonal and involve both the conjunctiva and the cornea, 
hence the name vernal keratoconjunctivitis (VKC). Other 
clinical forms are included in the classification of ocular allergy 
from which VKC must be distinguished: seasonal/intermittent 
allergic conjunctivitis (SAC), perennial/persistent allergic 
conjunctivitis (PAC), atopic keratoconjunctivitis (AKC), giant 
papillary conjunctivitis (GPC) and drug-induced dermato-
conjunctivitis. Amongst these, AKC is closest in appearance 
to VKC.1,2,17
This review focuses on the management challenges of VKC, 
a seasonal, recurrent, bilateral, chronic allergic inflammation 
of the conjunctiva and the cornea.2,6 The allergic response is 
triggered by an over-reaction of the body’s immune system 
to allergens or foreign bodies and tends to run a more severe 
course. 
It is also known as ‘seasonal conjunctivitis,’ ‘spring catarrh’ 
or ‘warm weather conjunctivitis.’.1 It is the only ocular disease 
to involve solely Type 1 hypersensitivity response mediated by 
IgE antibodies bound to the membrane of the mast cell in the 
conjunctival substantia propria.3,14 Attachment of the antigen 
to the IgE antibodies results in the release of pro-inflammatory 
mediators like histamines, leukotrienes, prostaglandins, 
tryptase, chymase, platelet activating factor and other chemo-
attractants. This results in increased vascular permeability and 
attraction of eosinophils and neutrophils.3,7,12
These pro-inflammatory mediators are responsible for the 
clinical pictures of the conjunctivitis.3 However, cytologic, 
biohumoral, immunohistologic and molecular biologic studies 
have suggested the involvement of T helper cell type 2 (Th-
2) lymphocyte mediated allergic reaction with additional 
hypersensitivity responses that are often ill-defined.7,12,13 Vernal 
keratoconjunctivitis is usually bilateral, but may occasionally 
be asymmetrical. It accounts for roughly 0.10 to 0.50% of 
patients with ocular diseases worldwide.8,18 However, unilateral 
VKC is rare.
The disease affects children between 3 to 16 years of 
age, though it may appear earlier than that and continue 
into adulthood. In some cases, it is often self-limiting and 
the symptoms resolve around puberty.6 It is more common 
among boys than in girls probably due to their persistent 
outdoor activities.1 Its predominance in male children, 
resolution at puberty and positive staining for oestrogen and 
progesterone receptors in conjunctiva of patients with VKC 
also suggest a hormonal component in the development of 
VKC.7,9,16 In addition, increased serum levels of interleukin-17 
(IL-17) and antinuclear antibodies, together with a high 
association with familial history of autoimmune disorders 
suggest additional mechanisms involved in the development 
of VKC.7,11,13 Multiple factors can contribute to the aetiology 
of VKC including environmental allergens, climate and genetic 
predisposition.7 However, the suggestion of a hereditary 
association still remains unclear as no clear direct correlation 
with specific genetic loci has been made.5 The disease is 
minimal in temperate climates compared to warm climates, 
and almost nonexistent in cold climates. It is severe in spring, 
summer and incidence falls in the winter. It is more common 
in Sub-Saharan Africa and the Middle East.1 
Though the name vernal implies a seasonal occurrence, the 
disease may be perennial (persisting throughout the year) or 
with acute exacerbations.18 Severe VKC greatly affects a child’s 
academic performance and ultimately impairs his quality of 
life. The corneal involvement in the disease known as vernal 
keratitis may be severe enough to interrupt a child’s education 
and ultimately affect his future potential. Besides, it can lead 
to permanent visual impairment if not adequately managed.15 
Vernal keratitis is characterized by a combination of punctate 
epithelial erosions and keratitis.3 Punctate epithelial erosions 
are areas of absent epithelium that stain with fluorescein. 
Punctate epithelial keratitis is caused by an influx of white cells 
into the corneal epithelium. The epithelium in this area stains 
with Rose Bengal, which stains devitalized cells.2,9 Keratitis 
epithelialis of Tobgy is the early phase of vernal keratitis, 
consisting of minute white dots in the epithelium which when 
coalesce, forming vernal ulcers known as shield ulcers.7,16 
Shield ulcers are distinctly indolent, oval in shape and most 
often found in the upper half of the cornea. The pathogenesis 
of these shield ulcers is believed to involve a combination of 
mechanical damage to the corneal epithelium by giant papillae 
and toxic epitheliopathy from inflammatory mediators secreted 
by eosinophils and mast cells.5,15 These ulcers are sterile but 
may, by chance, be infiltrated by bacterial pathogens giving rise 
to bacterial corneal ulcers. These ulcers can be differentiated 
from vernal shield ulcers, which are indolent and often have a 
plaque at the base. Shield ulcers occur in approximately 3% to 
20% of patients with VKC.7,15,16
Causes
The aetiology and pathophysiology of VKC remain unclear, 
but may be due to a longstanding allergic reaction of the body’s 
immune system to allergens.4 It is common in people who 
have other signs of allergic diseases such as hay fever, asthma, 
and eczema.4,6 Prominent causative allergens include pollen 
from trees, grasses and ragweed; animal dander; dust; smoke; 
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mould spores; hairs; dust mites; wool and feathers; perfumes; 
cosmetics; eye drops; and skin medicines.1,8
Symptoms
The symptoms are due to the release of histamines and other 
active substances by the mast cells, which stimulate dilation of 
blood vessels, irritate nerve endings and increase secretion of 
tears.7
Common symptoms include severe itching, tearing, 
photophobia (sensitivity to light), pain, eyelid swelling, 
irritation, blepharospasm, burning and foreign body sensation. 
Blurring of vision may occur when the cornea is involved. 
These complaints, especially itching, are made worse when the 
patient is exposed to a dusty, warm humid atmosphere, wind 
and bright light, or physical exertion associated with sweating, 
possibly due to increase in allergen count.3,6,8,16 
Signs
The disease is characterized by milky appearance of the 
conjunctiva, fine papillae in the lower tarsal conjunctiva 
and giant, flat-topped papillae resembling a ‘cobblestones’ 
in the superior tarsal conjunctiva (which is the hallmark of 
the disease).1,7 Tenacious mucus may form and adhere to the 
cobblestones. The conjunctiva may be swollen and hyperaemic. 
Thick, ropy strands of mucus or filamentary keratitis are 
present (mainly in severe VKC).16 Microscopic examination 
of the conjunctival biopsies reveal large numbers of scattered 
eosinophils and eosinophilic granules but these are less 
common on conjunctival smears. Basophils may also be present 
in the biopsy but not in the same proportion as eosinophils. 
High levels of proteins secreted by eosinophils (e.g. eosinophil 
cationic protein) have been found in the tears of VKC patients 
as well as atopic and allergic conjunctivitis. There are also 
low proportions of mononuclear and polymorphonuclear 
inflammatory cells in the exudates.1 
Clinically, vernal keratoconjunctivitis consists of the 
palpebral, the limbal and the mixed types.3,6 
The palpebral form of VKC is characterised by giant, flat-
topped papillae on the superior tarsal conjunctiva that gives a 
“cobblestones” appearance.6  Giant papillae consist of papillary 
conjunctival masses greater than 1mm in size on the upper 
tarsal conjunctiva, with a proliferation of collagen underneath 
the conjunctival epithelium. Its mechanism of formation is 
mainly epithelial thickening and fibroblast proliferation.5,7 
The presence of giant papillae signifies prolonged chronic 
inflammation. It may also indicate poor prognosis. The 
palpebral VKC is also characterized by sticky exudates and 
tightly packed papillae in the active phase of the disease which 
get more separated as the inflammation abates. Approximately 
50% of the patients with the palpebral form of VKC have 
corneal involvement which may range from superficial punctate 
keratopathy to well-demarcated sterile corneal shield-like ulcer 
(frank epithelial loss) located superiorly.6 This may heal leaving 
behind a vascularised scar. Frank epithelial loss (shield ulcer) 
results from the abrasion of the underlying cornea from the 
keratinised epithelium of the giant papillae. It also gives rise 
to the complaint of foreign body sensation.11 A fine fibrinous 
pseudomembrane that is enhanced by heat may accumulate 
on giant papillae and is known as Maxwell-Lyon’s sign.1 
(A pseudomembrane is an aggregate of coagulated exudates 
that is attached to an inflamed conjunctiva which when 
removed leaves behind an intact epithelium). A pseudoptosis, 
mostly unilateral, may be noted. The cause is quite unclear, 
but could be as a result of palpebral thickening, heavy giant 
papillae, chronic eye rubbing or inflammatory insult to the 
levator palpebrae superioris muscle.
Limbal VKC is prominent in black races and females.6 It has 
a better prognosis.3 The conjunctiva is thick, oedematous and 
hyperaemic. The papillae in this form are found at the limbus 
(corneal-scleral junction) mainly superiorly. At the top of each 
papilla are gelatinous white clumps of degenerated epithelial 
cells and eosinophils, called Horner-Trantas dots, seen mainly 
during the active phase of the disease.1,6 The conjunctival 
changes include hyperpigmentation, subconjunctival fibrosis, 
keratinisation and symblepharon. A pseudogerontoxon 
(arcus senilis-like haze) is often noted in the cornea adjacent 
to the limbal papillae.1,16 It is often seen as a waxing and 
waning grey-white lipid deposit in the peripheral, superficial 
stroma. Pseudogerontoxon is clinically important because it 
is an indication of previous allergic eye disease.  Papillae can 
be differentiated from follicles by their red centres which 
consist of dilated blood vessels at the core of the papillae, 
surrounded by inflammatory cells including lymphocytes, 
plasma cells and eosinophils. Papillae consist of hyperplastic 
conjunctival epithelium thrown into numerous folds and 
can only develop in the palpebral and bulbar conjunctiva at 
the corneo-scleral junction (limbus). Follicles, on the other 
hand, are most prominent in the forniceal conjunctiva and 
consist of hyperplasia of lymphoid tissue within the stroma. 
They are clinically seen as multiple, discrete, slightly elevated 
lesions reminiscent of small grains of rice surrounded by 
tiny blood vessels.3 Follicles are commonly seen in viral, 
chlamydial infections, Parinaud oculoglandular syndrome and 
hypersensitivity to topical medications. 
The mixed form of VKC has the characteristic features of 
both the palpebral  and the limbal forms.
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Micropannus is often common in both palpebral and limbal 
VKC, but gross pannus is unusual.1 Neovascularisation of the 
cornea may follow.6 Conjunctival scarring usually does not 
occur unless the patient is treated with cryotherapy, surgical 
removal of papillae, irradiation or other damaging procedures.1 
Impairment of vision is common in cases with shield ulcers 
and corneal plaques.  The disease may be associated with 
ectatic corneal diseases such as pellucid marginal degeneration 
and keratoconus.1,3 Amblyopia seen among patients with VKC 
may be caused by corneal opacity, irregular astigmatism and 
keratoconus.16
The palpebral form of VKC is more prevalent In Europe 
and the Americas, whereas the limbal and the mixed forms 
are common in Africa and Asia respectively, with some 
geographical variation.5,7
Challenges
Allergic eye diseases and vernal keratoconjunctivitis, in 
particular, have been a thorn in the flesh of eye care providers 
and patients in warm climates. This ugly scenario has been 
attributed to the large percentage of the populace affected by 
the disease.6 Khaksar  and Bagheri,  in an epidemiological study 
of VKC in Kashan (in Iran), stated that approximately 3% of 
the patients seeking eye care services in outpatient clinic of 
the Ophthalmology Department BVH, Bahawalpur had VKC 
and more than 80% are below 18 years of age.10 Also, Hall 
and Shilio  of the Ophthalmology Department, Kilimanjaro 
Christian Medical Centre, Moshi, Tanzania stated that over 
25% of the total children seen at a tertiary referral paediatric 
eye clinic in East Africa had VKC and more of the children 
came flocking to screening clinics complaining of itchy eyes.6 
The unstable and unpredictable global weather conditions 
have increased the vulnerability of affected individuals who 
are unable to predict effectively exposure periods and take 
adequate precautionary measures.
The management is time-consuming and frustrating both 
to the patients and the eye care providers, in that patients keep 
coming with the same complaint often without appreciable 
remedy.6 The patients often seek different eye clinics and 
medicine dealers in search of cure when symptoms become 
unbearable. Sometimes, they may have suffered the affliction 
many years before being properly diagnosed.
The morbidity rate of blindness from the disease is high. 
Some patients that develop corneal ulcers may go blind due 
to corneal opacification.6 Other visual impairments such as 
glaucoma, dry eye syndrome, or cataract may result from 
uncontrolled use of steroids.16
Some continents like Sub-Saharan Africa and the Middle 
East, where the disease is more prevalent, are populated 
by individuals living in abject poverty and unhygienic 
environment. The high costs of the potent topical medications 
for the disease are beyond the means of the populace. This 
compounds the problem, leaving the patients with no option 
but resort to the use of local concoctions, which may give 
rise to diverse ocular complications and blindness. On the 
other hand, some of these potent ocular medications are 
not readily available. When available, some are adulterated, 
thereby making disease response inadequate. The available 
effective drugs may not be judiciously used by some patients 
as prescribed, thus limiting management. 
Inadequate man power to cater for the ever-increasing 
number of patients with ocular allergy is another problem. 
This has led to patronization of quacks with the resultant effect 
of visual impairment.
It is often said that he who is not informed is deformed. Lack 
of awareness of the disease by the patient, and the inability of 
some eye care providers to provide the patients with firsthand 
information of the nature, course and predisposing factors 
associated with their ailment constitutes another setback. This 
leaves the patient with the option of seeking information from 
the wrong channel which may even aggravate their condition.
The lack of standardized diagnostic criteria, absence of 
an established gold standard treatment, and lack of common 
language among physicians regarding the severity of VKC 
renders the disease more difficult to diagnose and treat.16  
In order to tackle these challenges directly, eye care 
providers should have first-hand information of the nature of 
the disease, recognition of its clinical features and potential 
blinding complications.6
Given the chronic nature of the disease, regular and 
adequate treatment through proper patient education 
regarding what to expect and the pit falls of therapy as well as 
long term follow-up is essential.18 This can be backed up by 
patient information leaflets as a way of breaking the cycle of 
inadequate treatment, misuse of medication, noncompliance, 
and resulting frustration.6 Discouragement of self-medication 
through effective enlightenment campaigns by eye care 
providers and provision of potent low cost ocular medications 
will go a long way toward ameliorating the problem. However, 
psychological support may be necessary in severe cases. 
Training and re-training of eye care professionals is of 
utmost importance to equip them with the latest developments 
in eye care profession. The use of community health care 
providers in reaching out to the vast populace in the rural 
areas far from health facilities should be encouraged. The 
public  should be advised about the benefits of personal and 
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environmental hygiene. Government and non-governmental 
organizations should collaborate in bringing heath care 
resources closer to the people for prompt and effective 
dispensing of treatment. 
Medical outreach programmes can be organized by the 
eye care professionals. Policy makers should endeavour to 
incorporate physical and health education in the school 
curriculum from primary to tertiary level to raise awareness of 
common ocular and other diseases. 
Government and non-governmental agencies should 
support medical research institutes and researchers with 
readily available funds and research grants. This will permit 
in-depth study of the disease and other ailments, with the 
aim of establishing standardized diagnostic criteria and a 
universally acceptable model of treatment.  
Treatment 
Vernal keratoconjunctivitis treatment involves alleviating 
the severity of the symptoms and preventing serious sight 
threatening complications. Permanent visual impairment can 
result from improper management of the disease.
The first step in the management of vernal 
keratoconjunctivitis is patient counselling. This is aimed at 
educating the patients on the nature, course and predisposing 
factors associated with the diseases.6 This will go a long way 
toward good adherence to the symptomatic management and 
avoidance of those environmental factors that may exacerbate 
the disease.
Topical mast cell stabilizers such as Alomide (Lodoxamide 
Tromethamine 0.1%), Alocril (Nedocromil Sodium 2%), 
and Crolom (Cromolyn sodium 4%) can be given in mild to 
moderate cases. They should be used regularly 3-4 times daily 
even when the symptoms have subsided to prevent the release 
of histamines from the mast cells. However, their use after the 
symptoms have occurred is of no value because their action 
is not immediate. They can be used for a long time, for they 
do not have the side effects of steroids. They are not usually 
adequate when the eyes are severely inflamed, when keratitis is 
present, or when there is a vernal ulcer. In these cases, topical 
steroids should be used to control the inflammation and mast 
cell stabilizers added as adjunctive therapy to give room for 
steroid tapering.3,5,6,7
Topical mast cell stabilizing- antihistamines such as livostin 
(Levocabastine hydrochloride 0.05%), patanol (Olapadine 
Hydrochloride 0.1%), zaditor (Ketotifen Fumarate 0.025%) 
and optivar (azelastine 0.05%) are good in managing mild to 
moderate cases.1,14 They act by reducing eosinophil activation 
and cytokine release.1 Oral antihistamines like Benadryl 25mg 
three times daily are also effective in mild to moderate cases 
in suppressing other symptoms of allergy but are of limited 
benefit in the eye.3
Topical decongestants such as epinephrine, naphazoline, 
and phenylephrine may play an effective role in mild to 
moderate VKC by producing vasoconstriction of superficial 
vessels, reducing hyperaemia, chemosis and other symptoms 
and by retarding the release of chemical mediators.11,17 Cold 
compresses, ice packs, preservative free artificial tears and 
ointments may play a helpful role in diluting the antigens, 
thereby reducing the severity of the symptoms, but are 
irrelevant in managing onset of keratitis. Sleeping (if possible 
also working) in a cool, air conditioned room can keep the 
patient reasonably comfortable. Probably the best remedy of 
all is to move to a cool moist climate.1,8
Topical non-steroidal anti-inflammatory drugs (NSAID) 
such as Acular (Keteorolac Tromethamine 0.5%), Diclofenac 
(voltaren) may provide significant symptomatic relief in 
moderate cases, but may retard the re-epithelialization of 
a shield ulcer.16 These agents act primarily by blocking the 
synthesis/release of prostaglandin through inhibition of 
cyclooxygenase, the enzyme that catalyses the conversion 
of arachidonic acid to prostaglandins.1 However, a careful 
follow-up is required as corneal melting has been reported 
after instillation of several types of NSAID.5
A short term course of systemic and or topical steroids such 
as Pred Forte, Lotemax (loteprednol etabonate 0.5%), Alrex 
or Pred Mild (prednisolone 0.12%, Allergan) and Efemoline 
followed by cold packs and histamine blocking agents can be 
used in severe cases as well as in those presenting with corneal 
involvement.7,14
Steroids should be avoided as the first line of defence in 
the treatment of mild to moderate VKC  because of their 
long term side effects.16 In using steroids, those with low 
intraocular absorption such as Fluorometholne, Lotoprednol, 
or Efemoline should be used first as they have less or no 
effect in intraocular pressure (IOP). Stronger steroids such 
as Prednisolone, Dexamethasone, or betamethasone should 
be used with adequate supervision only when the above-
mentioned first choice steroids have proven ineffective. 
Steroids inhibit mediator biosynthesis and disrupt 
intercellular communication by preventing the release of 
lymphokines. They are the most effective and best proved 
treatment for VKC especially in active keratitis.5,17
Steroids should be used frequently initially and tapered to 
a stop once the acute stage of the disease is stabilized (usually a 
few weeks). Prolonged use of steroids should be avoided since 
it is too often followed by herpes simplex keratitis, increase 
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in IOP, cataract, glaucoma, delayed wound healing, dry eye 
syndrome, fungal and other opportunistic corneal ulcers.6,9,16
Supratarsal injections of both long acting steroids 
(e.g. Triamcinolone acetonide), and short acting steroids 
(e.g. Dexamethasone sodium succinate) may be used for those 
not responding to conventional treatment.6,10 
Steroid-antibiotic combination eye drops should be avoided 
as VKC is an allergic inflammation rather than an infection. 
In cases of secondary bacterial infection, topical antibiotic eye 
drops and/or ointment should be used to provide adequate 
therapeutic dose to combat the infection. 
Topical Cyclosporine A (CsA) drops (1-5%) e.g. 
Restasis, in olive oil or castor oil 4 times a day can be used as 
an alternative to steroid injection in severe cases.6,7,12 
Cyclosporin A is a calcineurin inhibitor that binds to 
cyclophilin, an intracellular protein, which in turn prevents 
the formation of interleukin-2 and the subsequent recruitment 
of activated T cells. It also inhibits histamine release from 
mast cells. Through reduction of IL-5 production it may 
reduce the recruitment and the effect of eosinophils on the 
conjunctiva.12,16,19 It has been used successfully in several 
studies to treat severe cases of VKC. It does not cause an 
increase in IOP.  It is a potent immunosuppressive agent used 
in the prevention of transplant rejections. It plays an important 
role in the healing of vernal shield ulcers but recurrences may 
occur at lower concentrations, which may mandate increasing 
the concentration. Its use in VKC management is limited due 
to its high cost and unavailability of commercial preparation 
of topical CsA in higher concentrations.13,16,19 
Tacrolimus is a potent drug, similar to CsA in its mode 
of action, but chemically distinct. Case series and placebo 
controlled randomized control clinical trial has shown a 
beneficial effect of tacrolimus ointment (0.1% to 0.3%) and 
drops (0.005% and 0.1%) in severe VKC. However, it irritates 
the eyes and makes patients susceptible to opportunistic 
infections and herpes simplex keratitis. It has a limited use in 
the developing world due to its high cost.21
Tenacious mucus adhering to the cobblestones in 
particular, thick, ropy strands of mucus as well as filamentary 
keratitis can be treated with Acetylcysteine. It is known to 
break the disulfide bonds, thereby dissolving the mucus.16 It 
is formulated from commercially available Mucomyst, diluted 
to a 5% or 10% solution with artificial tears, and is applied 
four times a day. It is also effective in treatment of shield ulcer 
in conjunction with aggressive cycloplegia (homatropine 5% 
or scopolamine 0.25%, bid) and topical antibiotic drops-
Ciloxan (ciprofloxacin, Alcon); Ocuflox (ofloxacin, Allergan) 
or Quixin (levofloxacin, Santen).11,16,19
Short-term, low-dose, topical mitomycin-C 0.01% has 
been considered for treating acute exacerbations in patients 
with severe VKC refractory to conventional treatment. 
It inhibits fibroblast proliferation and decreases mucus 
discharge, conjunctival hyperaemia and limbal oedema. 
However, unavailability of commercial topical preparations, 
limited comparative studies, and the lack of data on the safety 
profile and long-term outcomes are major limitations in 
recommending mitomycin for the treatment of VKC.16,20
Debridement/lamellar keratectomy of early mucus plaques 
at the base of the vernal ulcer and intensive topical steroids 
may speed up the re-epithelialization process. Also, low-water-
content bandage contact lenses are helpful in the treatment of 
these defects as well as reducing the interaction between the 
lid and cornea.5,6,16
Free autologous conjunctival graft resection of giant 
papillae facilitates the re-epithelialization of non-healing shield 
ulcer. Persistent corneal epithelial defects can be treated by 
amniotic membrane transplantation and limbal epithelial cell 
transplantation. Vision improves significantly after transplant. 
Corneal epithelial cell transplants could be beneficial when 
amniotic membrane transplant is not sufficient to restore the 
ocular surface.3,12,16
Other general measures in the management of VKC 
include: dark goggles (sunglasses), visors and caps to prevent 
photophobia. Identification of the non-specific triggering 
agents which could aggravate symptoms such as strong wind, 
dust, air pollutants and strong sunlight and avoiding them are 
of optimum importance but this is often impractical. Frequent 
hand and face washing with clean cool water or rinsing the 
eye with an adequate amount of cool normal saline is also 
important to reduce the severity of the symptoms and avoid 
secondary infection.
 Case Presentation
A 13-year-old male patient presented to the clinic with 
complaints of severe itching, discharge, blurry distance vision 
with object distortion and discomfort with light in both eyes. 
The problem started about two and a half months earlier and 
he had been on chloramphenicol eye drops to no avail. Further 
probing into his case revealed that his condition was usually 
made worse whenever he visited their poultry house. He had 
been known to have seasonal allergies right from birth and had 
never had an eye examination before. There is also a family 
history of eczema.
Clinical examination revealed the following: unaided 
visual acuity OD: 20/60 (6/18), PH: 20/40-2 (6/12-2). OS: 
20/60+2 (6/18+2), PH: 20/40 (6/12). The patient was moderately 
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photophobic with no relative afferent papillary defect (RAPD) 
in both eyes. The intraocular pressure (IOP) was OD: 
16mmHg and OS: 17mmHg. Slit lamp examination revealed 
dense papillary reaction with some thick strands of mucus 
adhering on the palpebral surface of the upper lids. There was 
also moderate papillary reaction of the limbal conjunctiva 
superiorly and a dark brownish colouration of the conjunctiva 
around the limbus, more profound at the palpebral fissure in 
both eyes. Dilated fundus examination revealed normal disc, 
macula, vessels and peripheral fundus in both eyes. Refraction 
before dilated funduscopy gave the following results.
Objective refraction (Autorefractor):
OD: +0.25 - 3.50 x 045 VA 20/40 (6/12); OS: +0.75 – 5.50 x 130 
VA 20/40+2 (6/12+2)
Subjective refraction:
OD: Pl – 2.00 x 15 VA 20/40 (6/12); OS: +0.25 – 3.50 x 115 VA 
20/40+2 (6/12+2)
The patient was diagnosed with mixed vernal 
keratoconjunctivitis; animal danders were suspected as the 
triggering agent. He was started on topical steroid Lotemax 
(Loteprednol etabonate 0.5%) twice daily due to the severity 
of the disease and topical antihistamine/mast cell stabilizer- 
Zaditor (Ketotifen fumarate 0.025%) twice daily. He was 
advised against visiting their poultry house or other animal 
farms outside their home, coming in contact with pets, and 
to discontinue the application of chloramphenicol eye drops. 
He was also advised on the need for proper personal hygiene, 
regular washing of hands and face with cool clean water, 
scrubbing of the eyelash with cotton tipped applicator soaked 
in normal saline to remove the dry exudates. The subjective 
refraction result was not dispensed due to the suspected 
compromise in the topography of the corneal surface due to 
the active nature of the disease. On his follow-up visit two 
weeks later, there was an improvement of the limbal papillae 
but the superior tarsal conjunctival papillae persisted together 
with the dark limbal colouration. He was advised to continue 
with the two drugs and to return to clinic after one week. On 
his next visit one week later, there was a complete resolution 
of the limbal papillae and some resolution of the dark limbal 
colouration but the superior tarsal papillae persisted with only 
moderate clearance of mucus adherence. He was then given 
a supratarsal injection of 0.5ml triamcinolone under local 
anaesthetic drops as follows: The conjunctiva was anaesthetized 
with 4% lidocaine hydrochloride drops instilled to both eyes 
every minute for five minutes, after the course of treatment 
has been explained and his consent obtained. The upper eyelid 
was everted. 4% lidocaine hydrochloride soaked cotton tipped 
applicator was dabbed over it for about 1 minute. The patient 
was asked to look down and a 26 gauge needle of 1ml syringe 
containing 0.5ml of triamcinolone acetonide (40mg/ml) was 
inserted through the conjunctiva into the supratarsal space 
between the conjunctiva and the Mueller’s muscle.  Adequate 
care was taken to avoid the marginal blood vessels. 0.5ml of 
triamcinolone acetonide was injected after ensuring proper 
placement of the needle. The potential space between the 
conjunctiva and Mueller’s muscle was ballooned indicating 
successful placement of the injection. Both eyes were injected 
and a pressure pad was applied for 2 to 3 minutes to reduce the 
ballooning of the lid and help spread the injection evenly.  He 
was maintained on Zaditor after the injection but discontinued 
topical steroid after tapering it one drop daily for 1 week. On 
his next visit 2 weeks later there was a total resolution of the 
papillae and the limbal brownish colouration could hardly 
be noticed. There was no significant increase in the IOP as it 
stood at 17 mmHg in both eyes. His final optical prescription 
after resolution was OD: Pl -1.25 x 35 VA 20/30+2 (6/9+2) and 
OS: Pl – 2.00 x 145 VA 20/20-3 (6/6-3) with VA in both eyes 
as 20/20-2 (6/6-2). The spectacle prescription was dispensed to 
him in photochromic form to enhance his vision (as well as 
eliminating image distortion) and reduce the effect of light. 
He was placed on regular use of Zaditor to avoid sudden 
reoccurrence. He was counselled on the nature of his disease 
and the need to avoid coming in contact with the suspected 
predisposing agent and the importance of regular clinical 
checks despite resolution.
 
Discussion
Vernal keratoconjunctivitis is a seasonal, bilateral, recurrent 
allergic inflammation of the conjunctiva and the cornea.2,6 The 
disease affects children between 3 and years of age, though it 
may appear earlier than that and continue into adulthood. 
In some cases, it is often self-limiting and the symptoms 
resolve around puberty.6 It is more common among males 
than females.1 It is characterized by the presence of bilateral 
palpebral and/or bulbar conjunctival papillae, photophobia, 
tearing, burning, thick, ropy, yellow mucoid discharge and 
mild to severe itching.3,6,7 It has a high incidence in the warm, 
dry climates with fewer incidences in cooler climates.1 It is 
associated with a positive family history for atopic diseases 
such as asthma, rhinitis, hay fever and eczema.4,6,7 In VKC, an 
allergic response is triggered by an over-reaction of the body’s 
immune system to allergy or foreign bodies. This leads to the 
release of histamines and other mediators by the immune 
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system resulting in itching, burning and runny eyes that may 
become red and inflamed. Classically, it is thought of as a 
type 1 IgE-mediated hypersensitivity reaction. However, 
it has been suggested that there is a cell-mediated Th-2 
involvement.3,7,13 Laboratory testing of the conjunctival 
scrapings reveals higher numbers of eosinophils.1 Finding 
eosinophilic granules can aid the diagnosis but is not necessary, 
except in difficult cases, as VKC is easily diagnosed clinically 
based on history, signs and symptoms.14,16
The main idea in the management of VKC is to minimize 
inflammation as well as to reduce complications until the 
disease subsides. Topical treatment is preferable and more 
effective than systemic. Topical mast cell stabilizers and 
antihistamines or a combination of both are the first line of 
choice in the management.14,16 The drugs are effective for mild 
to moderate cases and can be used for a long period without 
adverse effect. Severe and unresponsive cases are treated with 
steroids and cyclosporine. Non-steroidal anti-inflammatory 
eye drops are also useful in mild cases. However, detection 
and avoidance of the triggering agents (allergens), cold 
compresses, and moving to a cooler climate is a good strategy 
in ameliorating the severity of the disease.1,6,14
In this case, the blurry distance vision resulted from 
astigmatism brought about by the compromise of the corneal 
surface due to the activeness of the disease. (This manifests 
from the discharge, limbal papillae, tarsal palpebral papillae 
pressing on the eyeball and constant rubbing of the eye due to 
intense itching which may slightly alter the topography of the 
cornea). The photophobia results from the painful contraction 
of an inflamed iris or the excitation of the many pain fibres 
of the cornea. The discharge comes from the migration of 
inflammatory cells (e.g. eosinophils) from the conjunctival 
stroma through the epithelium to the surface. Here they 
combine with fibrin and mucus from the goblets cells to 
form the conjunctival exudates1 Topical mast cell stabilizer 
(Zaditor) and topical steroid (Lotemax) were prescribed 
due to the severity of the disease. These produced a good 
response in resolving the limbal component of the disease. The 
unresponsive tarsal palpebral component was taken care of by 
supratarsal injection of 0.5mL triamcinolone acetonide which 
gave a complete resolution and disappearance of the brownish 
colouration. The Zaditor was continued after the resolution 
mainly to avoid a relapse. There was no significant change in 
the IOP of the patient due to adequate monitoring and close 
supervision of the drug administration. The refraction result 
obtained before the resolution of the disease was not dispensed 
due to its unreliability brought about by the compromise 
of the corneal surface as a result of the active nature of the 
disease. However, the result obtained after complete resolution 
which gave a significant visual improvement was dispensed in 
photochromic form to reduce the patient’s sensitivity to light. 
Eliminating exposure to the identified triggering agent (animal 
dander) accelerated the early resolution and should prevent 
recurrence.
Differential diagnosis includes giant papillary conjunctivitis 
due to retained foreign body, exposed sutures and contact lens 
related problems, chlamydial and gonococcal conjunctivitis, 
chronic blepharitis, atopic keratoconjunctivitis, viral and toxic 
conjunctivitis, SAC, PAC, phlyctenulosis, band keratopathy 
and floppy eyelid syndrome.2,8,14 This is possible through a 
comprehensive clinical history and ocular examination. AKC 
rarely occurs in childhood and patients tend to complain of a 
watery discharge (mucus discharge in VKC).
Conjunctival scraping reveals eosinophils to a greater degree 
in VKC, the inferior palpebral conjunctiva is more involved 
(usually superior in VKC), and there is often an associated 
blepharitis (less likely in VKC).1,3 Differentiating VKC from 
the other allergic conditions is usually fairly straightforward: 
corneal changes are rarely seen in SAC and PAC; in GPC, the 
ocular irritation is associated with contact lens wear; and in 
drug induced dermato-conjunctivitis, the offending agent can 
usually be identified. Symptoms of infective conjunctivitis 
are normally worse first thing in the morning and the eyelids 
are often gummed together on awakening due to discharge. 
In viral conjunctivitis, small conjunctival haemorrhages are 
common. Tenderness and swelling of the preauricular nodes 
is indicative of viral conjunctivitis. Bacterial conjunctivitis is 
characterised by purulent discharge.1,4,17
In conclusion, since a gold standard treatment for VKC has 
not been established, understanding of the pathogenesis of the 
disease by eye care providers may lead to better therapy for the 
patients with this unfortunate disease.
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